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Abstract Erythropoietin (EPO) quantification during cell
line selection and bioreactor cultivation has traditionally
been performed with ELISA or HPLC. As these techniques
suffer from several drawbacks, we developed a novel EPO
quantification assay. A camelid single-domain antibody
fragment directed against human EPO was evaluated as a
capturing antibody in a label-free biolayer interferometry-
based quantification assay. Human recombinant EPO can
be specifically detected in Chinese hamster ovary cell su-
pernatants in a sensitive and pH-dependent manner. This
method enables rapid and robust quantification of EPO in a
high-throughput setting.
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HRP Horseradish peroxidase
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Introduction
Erythropoietin (EPO) is a 34 kDa glycoprotein hormone
produced in the adult kidney and in the fetal liver. It
controls erythropoiesis by stimulating maturation of ery-
throid precursor cells in the bone marrow through inter-
action with the EPO receptor expressed on its surface,
resulting in increased numbers of red blood cells [1]. EPO
comprises a 165 amino acid protein with 40 % of its ma-
ture molecular weight accounted for by carbohydrates. The
structure contains three N-glycans located on asparagine
residues at positions 24, 38, and 83 and one mucin-type
O-glycan located on the serine 126 residue [2, 3]. Due to
this complexity, EPO intended for therapeutic use is pro-
duced in mammalian host cells, mainly in Chinese hamster
ovary (CHO) cells. Recombinant human EPO is now
available in sufficient amounts for clinical use in the
treatment of anemia that results from chronic renal failure
[4].
Accurate quantification techniques are critical for the
selection of high producing clones during stable cell line
development and optimization of bioreactor titers in pro-
duction. Traditional measurement methods include ELISA,
HPLC or densitometric analysis of Western blots. Despite
the widespread adoption of ELISA in industry, there are
several drawbacks to this method, e.g., high reagent cost,
long total assay time, and extensive ‘hands-on’ time re-
sulting in a high variability in results and susceptibility to
human error. Due to its high degree of automation, ro-
bustness, and reproducibility liquid chromatography is the
workhorse of the biopharmaceutical laboratory, but
throughput is limited to at most 4–12 samples per hour.
Quantitative Western blotting is time consuming and
challenging to perform properly, and it has therefore not
been adopted on a large scale. Faster times-to-results,
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better consistency, and less human intervention are the
prerequisites for the development of high-throughput
laboratory quantification methods.
Bio-layer interferometry (BLI) is an emerging tech-
nology that offers label-free quantification of antibodies
and other proteins [5, 6]. Conventional BLI quantification
assays use an immobilized full-length antibody to achieve
the specificity to detect non-antibody proteins. Sensitivity
can be improved by employing a two-step ELISA-like
sandwich assay. To increase sensitivity even further a
three-step assay can be employed that uses a secondary
HRP-linked antibody to amplify detection signals. We
sought to develop a direct, one-step binding assay which
simplifies data interpretation and reduces assay time. For
this purpose, a camelid single-domain antibody fragment
directed against human EPO (anti-EPO VHH) was
evaluated as a capturing antibody. VHH fragments are the
smallest intact antigen binding domains derived from
heavy chain-only antibodies of camelids [7]. They are very
stable, highly soluble, and can easily be produced recom-
binantly [7, 8]. These binding domains have been suc-
cessfully applied as affinity ligands in chromatography
processes covering a variety of biotherapeutics [9–12], but
can also serve as target-specific capture reagents for label-
free technologies like BLI [13]. Since in BLI the shift in
wavelength, Dk, is a direct measure of the change in optical
thickness close to the surface of a biosensor tip, the use of a
VHH-based affinity ligand for capture that is only one-tenth
in size of a conventional 150 kDa antibody should lead to a
higher sensitivity in a BLI-based quantification assay.
Here, we describe the development of a sensitive and
robust EPO quantification assay using BLI. Our anti-EPO
VHH pre-coated immunosensors specifically bind EPO in a
pH-dependent fashion. The detection range using 200 s
incubation was 0.31–20 lg/ml spiked EPO. Although ini-
tially a large amount of unspecific binding in CHO cell
supernatants was detected, we were able to strongly reduce
these signals by increasing the ionic strength of the solu-
tion. Immunosensors can be regenerated using high-pH
conditions and reused for up to 10 rounds of quantification.
The results from an absolute EPO quantification corre-
spond well to those obtained using a commercially avail-
able EPO ELISA kit.
Materials and Methods
Cloning of Expression Constructs
Human EPO sequence was retrieved from Uniprot P01588
(EPO_HUMAN), PCR amplified, and cloned into
pcDNA3.1(?) vector using NheI and EcoRI sites. A
codon-optimized gene for EPO (coEPO) was ordered from
GeneArt and cloned in the same manner. The synthetic
sequences of Rituximab heavy and light chain were
ordered codon optimized for CHO from GeneArt. Se-
quences were based on protein sequences from the Drug-
Bank database under accession number DB00073. An
N-terminal signal peptide (MGWSCIILFLVATATGVHS)
was added to both protein sequences. Rituximab heavy
chain and light chain were cloned into the dual expression
vector pBudCE4.1 (Life Technologies, Carlsbad, CA,
USA). Empty vector control was pcDNA3.1(?). Rituximab
heavy chain was PCR amplified and cloned using SalI and
BamHI, and Rituximab light chain was PCR amplified and
cloned using NotI and XhoI.
Cell Culture and Transient Transfection
CHO-S suspension cells (Life Technologies) were grown
in CD-CHO medium (Life Technologies) supplemented
with 8 mM glutamine (Gibco/Life Technologies). Cells
were maintained in flat-bottomed 125 mL Erlenmeyer
flasks (Corning # 734-1885) and incubated at 37 C, 5 %
CO2 at 120 rpm. Passage cells culture was supplied with
1 lL/mL anti-clumping agent (Life Technologies). Anti-
clumping agent was removed one day prior to transient
transfection. 106 cells were transfected in 10 mL CD-CHO
supplemented with 8 mM Glutamine. Cells were trans-
fected with plasmid DNA at a concentration of 1.25 lg/106
cells using FreeStyleTM MAX reagent (Life Technologies)
according to the manufacturer’s protocol. Anti-clumping
agent was added to transfected cells 24 h post-transfection
at a concentration of 1.5 lL/mL. After 96 h, supernatants
were harvested by pelleting cells by centrifugation
(10 min, 1000 rcf) and 0.22-lm filtration. Conditioned
medium was generated by propagating CHO-S suspension
cells for 96 h and harvesting the supernatant. A stable cell
line of CHO-S expressing the codon-optimized gene for
EPO, a stable cell line of CHO-GS expressing His-tagged
EPO, and several transient transfected cell lines (CHO-S
expressing EPO and CHO-S expressing Rituximab) were
used in the ELISA comparison experiment. Where indi-
cated, supernatants were harvested on day 0, 1, 2, and 3
after transfection or expansion.
Assay Conditions
Biolayer interferometry was performed using an Octet
RED96 (Pall, Menlo Park, CA, USA). Streptavidin kinetic
grade biosensors (Fortebio 18-5021, Pall) were hydrated in
PBS, functionalized with the anti-EPO VHH biotin conjugate
(Life Technologies, cat.no: 7103372100) or a biotinylated
anti-EPO IgG (AB-286-NA, R&D systems, Minneapolis,
MN, USA) at 5 lg/ml in PBS, and blocked in PBS containing
1 lg/ml biocytin (120, 600, and 300 s, respectively). The
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anti-EPO IgG was biotinylated using the EZ-Link biotiny-
lation kit (Thermo Scientific, Rockford, IL, USA) with a
ratio of biotin:antibody of 1. EPO dilution series were pre-
pared using commercially bought EPO (Genscript, Piscat-
away, NJ, USA) and our in-house purified EPO at 20, 10, 5,
2.5, 1.25, 0.625, 0.3125 lg/ml in assay buffer (20 mM citric
acid, 0.1 % BSA (w/v), 0.02 % tween-20, pH 4.0). After
equilibration in assay buffer (120 s), EPO dilution series
were measured for 200 s. The pH-dependent binding profile
was tested with an EPO dilution of 10 lg/ml in 20 mM citric
acid, 0.1 % BSA (w/v), 0.02 % tween-20, pH 4.0, 4.6, 5.2,
5.8, 6.4, 7.0, 7.6. Immunosensors were equilibrated in the
same buffers without added EPO. Salt-dependent back-
ground reduction was performed using EPO and control
CHO supernatants adjusted to sample diluent conditions
with a 10 times concentrated buffer containing 200 mM
citric acid, 1 % BSA (w/v), 0.2 % tween-20, pH 4.0. NaCl
was added from a 5-M stock solution. Regeneration buffer
scouting was performed at an EPO concentration of 20 lg/
ml in the following solutions: 100 mM glycine pH 2.0,
100 mM phosphoric acid, 10 mM HCl, 10 mM Na2HPO4
pH 12, 5 M NaCl, 0.01 % Sodium dodecyl sulfate (SDS),
10 mM NaOH and 10 mM glycine pH 1.7. Regeneration was
performed using three cycles of 5 s incubation in regen-
eration solution and 5 s in neutralization solution (PBS).
Association was performed for 200 s with a shaking speed of
1000 rpm at 30 C. All assays were performed in 96-well
black microplates (Greiner Bio-One 655209). Octet System
Data Analysis 7.1 software was used to calculate binding
rates and absolute EPO concentrations (standard curve
equation: Dose response 4PL, binding rate equation: R
equilibrium). Storage incubation buffer was PBS containing
15 % sucrose.
Other Methods
His-tagged EPO was purified from the supernatant of a
stable hisEPO-expressing CHO-S cell line using a HisTrap
Excel affinity column and HiLoad 16/600 superdex 200 pg
gel filtration column (GE Healthcare, Piscataway, NJ,
USA), both according to the manufacturer’s instructions.
The Human EPO ELISA Kit (Stem cell technologies,
Vancouver, BC, Canada) was performed according to the
manufacturer’s instructions. Western blotting was per-
formed using a standard protocol except that a streptavidin-
peroxidase conjugate (Thermo Scientific) was used to vi-
sualize the VHH biotin conjugates. The VHH biotin con-
jugates were diluted to a working concentration of 5 lg/ml.
Rituximab was detected using a rabbit anti-human IgG
HRP-conjugate (Fisher Scientific, Waltham, MA, USA).
Anti-EPO monoclonal IgG (ab19485, Abcam, Cambridge,
UK) was diluted 1:1000.
Results
The VHH Ligand Specifically Binds EPO and Can
Be Applied as an Immunosensor
To verify the specificity of the anti-EPO VHH, Western
blotting analysis was performed on commercially avail-
able purified EPO and on supernatants of CHO cells
expressing either Rituximab or EPO. A supernatant from
cells transfected with an empty vector served as a
negative control. Biotinylated anti-EPO VHH was used as
the primary immuno-detection step, while a streptavidin-
HRP fusion was used for secondary detection. Due to its
extensive glycosylation, purified EPO migrates as a
smear of around 45 kDa (Fig. 1a, anti-EPO VHH, lane
1). In the supernatants from CHO cells expressing EPO a
similar smear was detected, while no background bands
or smears could be seen (Fig. 1a, anti-EPO VHH, lane
2). Rituximab and empty vector control supernatants
displayed no interaction with the anti-EPO VHH (Fig. 1a,
anti-EPO VHH, lane 3 and 4). A conventional anti-EPO
IgG served as a positive control and was used to confirm
the presence of EPO (Fig. 1a, anti-EPO IgG, lane 1 and
2). We also performed detection with a biotinylated VHH
raised against an unrelated glycoprotein in the same
manner as the anti-EPO VHH. We found that it does not
cross-react with EPO or any other proteins found in
CHO-S supernatants (Fig. 1a, unrelated VHH). The
presence of Rituximab was confirmed using an anti-hu-
man IgG (Fig. 1a, anti-hIgG). These results show that the
anti-EPO VHH is highly specific for EPO.
To construct an immunosensor, the anti-EPO VHH bi-
otin conjugate was immobilized onto streptavidin (SA)
biosensors. Functionalization of the tips with the VHH bi-
otin conjugate reproducibly resulted in a shift of 3.5 nm
(data not shown). Previous experiments where the anti-
EPO VHH was used as an affinity purification resin had
indicated that its binding behavior is severely affected by
changes in pH (Pim Hermans, unpublished observations).
To define the optimal pH-range for EPO detection, we
performed a pH scouting experiment using in-house puri-
fied EPO spiked into CHO supernatants. After equilibration
of previously prepared immunosensors in EPO-free pH-
adjusted buffer, we measured EPO for 200 s at pH 4.0, 4.6,
5.2, 5.8, 6.4, 7.0, and 7.6. Results show that the highest nm
shift within this pH range was detected at pH 4.0 (Fig. 1b).
At higher pH values the detected nm shift was severely
reduced, while around neutral pH almost no binding was
observed. We conclude that EPO binding under these ex-
perimental conditions was also strongly influenced by the
pH. Assay conditions were set to pH 4.0 in all subsequent
experiments.
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To assess the sensitivity of the anti-EPO immunosensors,
we prepared a dilution series of in-house purified his-tagged
EPO. Incubation for 200 s resulted in a maximum shift of
about 1.55 nm (Fig. 2a). The maximum shift decreased with
decreasing EPO concentrations, but even at the lowest con-
centration of EPO used (0.31 lg/ml), we still detected a shift
of about 0.05 nm. When we employed a conventional IgG as
a capture molecule, we only observed a maximum shift of
0.05 nm at 20 lg/ml EPO (Fig. 2b), while this signal rapidly
decreased at lower concentrations of EPO. We also com-
pared the results from in-house purified EPO to a dilution
series of commercially available EPO (Fig. 2c). The max-
imum shift of about 1.2 nm was lower than the shift detected
with in-house purified EPO. This decrease in signal was also
observed at the lowest concentration of EPO, where a shift of
about 0.02 nm was observed. Besides giving a higher signal,
the curves generated for our in-house purified EPO also ap-
pear to be more smoothed than the ones generated for com-
mercial EPO. The detection range of the anti-EPO VHH
immunosensors using 200 s incubation was 0.31–20 lg/ml
spiked EPO. These results show that our immunosensors can
detect a range of EPO with short incubation times.
Unspecific Binding in CHO Supernatants Reduced
by Increasing Ion Strength
Next we assessed if EPO could be detected in supernatants
from transient EPO expressions in CHO cells. Previous
prepared immunosensors were used to measure in EPO,
Rituximab, and empty vector supernatants. When measuring
empty vector and Rituximab supernatants, we detected a
large shift (*2.5 nm) that was comparable to the shift ob-
tained for an EPO containing supernatant (Fig. 3, top panel).
As these shifts were much larger than the shift detected for
the highest concentration of EPO in buffer (Fig. 2) and there
was little difference between control and EPO supernatants,
we speculated that there was a high degree of unspecific
binding within the supernatants. Upon raising the ionic
strength of the CHO supernatants by the addition of 250 mM
NaCl, the total nm shift was reduced strongly for all samples,
while an EPO-specific shift of about 1.2 nm was detected
(Fig. 3, middle panel). The unspecific binding of empty
vector and Rituximab supernatants was reduced almost
completely by increasing the ionic strength even further
(Fig. 3, lower panel). The EPO-specific shift was also further
reduced to about 0.7 nm. When the ionic strength was raised
even more, a high unspecific binding during equilibration
and a negative nm shift in supernatants was observed (data
not shown). These results show that addition of 500 mM
NaCl was optimal for the detection of EPO in CHO cell
supernatants as it minimizes unspecific signals, while only
the EPO-specific signal remains.
Regeneration and Storage of Functionalized
Biosensor Tips
Regeneration allows for reuse of immunosensors for sub-
sequent rounds of analysis and a reduction of costs. By
Fig. 1 Anti-EPO VHH specificity and pH dependence. a Western blot
of 0.1 lg purchased EPO (lane 1) and 10 ll of CHO cell supernatant
transfected with a vector containing the human EPO gene (lane 2), a
vector containing the Rituximab heavy and light chains (lane 3), and
an empty vector (lane 4). Blots were developed using anti-EPO VHH
(top panel), anti-EPO IgG (second panel), a VHH raised against an
unrelated glycoprotein (third panel), and an anti-human IgG-HRP
conjugate (lower panel). b Sensorgrams showing immobilized anti-
EPO VHH binding of in-house purified EPO (10 lg/ml) at the
indicated pH values
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disrupting protein–protein interactions between the immo-
bilized VHH and the analyte, the functionalized biosensor
can directly be reused for the next round of analysis or stored
for later use. Typically interactions can be efficiently dis-
rupted using low pH, high pH, high salt concentrations or
detergents. We decided to test the following regeneration
buffers: 100 mM glycine pH 2.0, 100 mM phosphoric acid,
10 mM HCl, 10 mM Na2HPO4 pH 12, 5 M NaCl, 0.01 %
SDS, 10 mM NaOH and 10 mM glycine pH 1.7. After pre-
conditioning through a single round of equilibration and
regeneration, the anti-EPO immunosensors were used to
measure a known concentration of EPO spiked into CHO
supernatant (Fig. 4). The nm shift of the first EPO mea-
surement was set as 100 percent and subsequent measure-
ments were expressed as a percentage thereof. The
regeneration conditions that show close to 100 percent re-
covery after repeated regenerations and show a low standard
deviation are good regeneration candidates. A rapid decrease
in binding was detected when using NaCl and SDS as re-
generation reagents, showing that the binding properties of
the anti-EPO VHH functionalized biosensors are severely
disrupted after incubation under these conditions. All the
low-pH conditions had a similar regeneration profile, where
the binding properties were still intact after the first incu-
bation, but decrease to 65–80 % recovery after several
rounds of regeneration (100 mM glycine pH 2.0, 10 mM
HCl and 10 mM glycine pH 1.7) or remain constant at about
85 % recovery (100 mM phosphoric acid). Regeneration in
10 mM NaOH leads to an increase in signal after the first two
binding events, but recovery rapidly decreased thereafter to
about 40 %. The other high pH condition tested (10 mM
Na2HPO4 pH 12) showed some fluctuation in binding re-
covery. After an initial increase, the recovery decreased to
about 96 % in the 4th regeneration. After that, the recovery
steadily increased to 109 % in the 9th regeneration. Despite
these fluctuations, the recovery percentage never differs
more than 9 % from the value obtained in the first binding.
The standard deviation was also the lowest under the con-
ditions tested. Sodium phosphate adjusted to a high pH was
therefore a suitable regeneration agent and it was used in
subsequent experiments. Functionalized tips are used in the
laboratory on a regular basis and have been stored for up to
2 weeks after a short incubation in storage buffer and sub-
sequent dehydration without loss of sensitivity.
Fig. 2 Immunosensor sensitivity. Representative sensorgrams show-
ing immobilized anti-EPO VHH binding of in-house purified EPO (a),
showing immobilized anti-EPO IgG binding of in-house purified EPO
(b), and showing immobilized anti-EPO VHH binding of commercial
EPO (c). EPO was present at the indicated concentrations
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Absolute Quantification Values of EPO Correspond
Well with Values Obtained by ELISA
The results obtained by the Octet quantification assay were
compared to a commercially available ELISA sandwich
assay. Analyses were performed on supernatants from a
panel of stable and transient transfected cell lines harvested
at different time points. Absolute concentrations of EPO
were calculated by comparison with a calibration curve
generated from three separate dilution series of in-house
purified EPO (Fig. 5a) or from the EPO dilution series
included in the ELISA kit. No or very little EPO was
Fig. 3 Background reduction by increased ionic strength. Sensor-
grams generated using supernatants of CHO cells transfected with an
empty vector (dotted line), a vector containing the human EPO gene
(solid line), or a vector containing the Rituximab heavy and light
chains (dashed line). NaCl was added at the indicated concentrations
Mol Biotechnol
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detected in the Rituximab control supernatant (Fig. 5b) and
these values were comparable to the values obtained from
the empty vector blank supernatant. Although minor dif-
ferences can be observed, native and tagged EPO con-
centrations in stable and transiently transfected cell lines
correspond well between the two assays (Fig. 5b). An in-
crease in titer can be observed for the EPO samples taken at
different time points. The three EPO supernatants har-
vested from a transient transfected CHO-S cell lines differ
from each other in EPO concentration. Furthermore, sam-
ple CHO-S EPO 1 and 2 also show the largest difference in
concentration between the two assays. In general, the ab-
solute concentrations acquired by our novel method agree
very well with the values obtained by ELISA.
Discussion
We present here a novel method to quantify secreted EPO
produced in CHO cell lines. To the best of our knowledge,
no prior studies describe a BLI-based quantification assay
for non-antibody proteins. A method has been described for
the quantification of Recombinant Human Factor IX in
bioreactor harvests using a conventional antibody [14], but
the method is only accessible through the website of For-
tebio, the company that produces the Octet BLI system. In
this work, we employ a biotinylated VHH to increase
sensitivity and facilitate data interpretation. Application of
a VHH as an immunosensor offers increased sensitivity
over a conventional IgG in the one-step binding assay
described here.
Concentration or clean-up of CHO cell supernatants is
not needed, but samples need to be adjusted to the right pH
and ionic strength. In addition, samples may need to be
diluted to an EPO concentration below 20 lg/ml. In these
experiments the lower limit of detection was 0.31 lg/ml of
spiked EPO. Using a full 96-well microplate including two
columns for regeneration and neutralization, we were able
to measure 80 samples in 45 min using only 8 biosensors.
As the VHH can be recovered and stored after construction
of the immunosensor, the total cost for measuring a full
plate is about €40. The method offers a very rapid and
facile way to determine EPO titer as compared to ELISA or
HPLC analysis. Because of its short setup and analysis
time, it is especially well-suited for bioreactor sampling or
for the selection of high producing clonal cell lines.
As shown by the comparison with ELISA, addition of a
His-tag to the native EPO protein sequence, expression in
different cell lines and stable versus transient expression
does not alter binding to the immunosensor and thus does
not influence absolute quantification. The differences we
observed between in-house purified EPO and commercial
EPO—lower nm shift and a more ‘noisy’ signal—are not
readily explainable, but could be caused by deviations from
the concentration declared by its manufacturer, by loss of
sensitivity due to buffer additives like phosphates, or by
differences in post-translational modifications. As the ab-
solute quantification values of EPO calculated from a di-
lution series of in-house purified EPO agree well with the
values obtained by ELISA, these preparations are used as
calibration in our laboratory.
It is important to recognize that the extensive glycosyla-
tion on EPO may influence the results obtained by BLI
quantification. A proteinaceous epitope is suggested by the
observations that anti-EPO VHH is able to cross-react with
non-glycosylated EPO derived from Escherichia coli by
Western blotting and by its binding affinity of*2 nM (Pim
Hermans, unpublished observations). However, as its
molecular mass consists of more than 40 % carbohydrates,
deglycosylation will influence optical thickness close to the
surface of a biosensor tip and thus the amount of shift which
can be achieved. Deglycosylation will therefore lead to an
underestimation of the actual concentration. If an introduced
glycosylation site or a more extensive glycosylation pattern
affects the epitope recognized by the anti-EPO VHH, binding
may be completely abolished. The method described here is
therefore not well suited for studies where a drastic change in
glycosylation pattern is expected.
The experiments described here were performed with SA
kinetic grade biosensors. Sensitivity could possibly be im-
proved using super streptavidin (SSA) biosensors or the re-
cently introduced high precision streptavidin (SAX)
biosensors. The SAX biosensors have been specifically de-
veloped by Fortebio to perform high-precision
Fig. 4 Biosensor regeneration. Wild-type CHO-S supernatants
spiked with in-house purified EPO were measured nine times after
an initial round of pre-conditioning. The first round of binding was set
at 100 % and subsequent rounds of binding were expressed as a
percentage thereof. Regeneration was performed in the indicated
solutions. Standard deviation is indicated above the columns
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quantification, but were not available yet during the de-
sign of this study. It remains to be seen whether these
biosensors can improve the sensitivity of the assay de-
scribed in this work. The throughput of this assay can also
be improved using the Octet RED384 or HTX BLI plat-
forms. The method is a promising candidate for further
establishment and cross-validation against current refer-
ence methods. Moreover, the concept presented here can
easily be modified using VHH ligands directed towards
other biotherapeutic (glyco) proteins, using other types of
small binding ligands like DARPins [15] or adapted for
other label-free detection systems like those based on
surface plasmon resonance (SPR).
Acknowledgments Stefan Kol and Thomas Beuchert Kallehauge
would like to thank the Novo Nordisk Foundation for funding.
Conflicts of interest Pim Hermans and Simon Adema are em-
ployees at BAC BV, Life Technologies, a Thermo Fisher Scientific
brand, located in Naarden, The Netherlands. These authors ac-
knowledge that there is a potential conflict of interest related to their
relationship with BAC BV, Life Technologies and attest that the work
contained in this research report is free of any bias that might be
associated with the commercial goals of the company.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Lee, J. S., Ha, T. K., Lee, S. J., & Lee, G. M. (2012). Current state
and perspectives on erythropoietin production. Applied Microbi-
ology and Biotechnology, 95, 1405–1416.
2. Lai, P. H., Everett, R., Wang, F. F., Arakawa, T., & Goldwasser,
E. (1986). Structural characterization of human erythropoietin.
Journal of Biological Chemistry, 261, 3116–3121.
3. Krantz, S. B. (1991). Erythropoietin. Blood, 77, 419–434.
Fig. 5 Comparison of Octet
and ELISA absolute
quantification. a Standard curve
generated from dilution series of
in-house purified EPO of known
concentration using end-point
values. Samples were run in
triplicate. b Absolute EPO
concentrations were determined
of supernatants harvested from a
stable cell line of CHO-S
expressing the codon-optimized
gene for EPO (coEPO), a stable
cell line of CHO-GS expressing
His-tagged EPO, and several
transient transfected cell lines
(39 CHO-S expressing EPO
and CHO-S expressing
Rituximab). Where indicated,
supernatants were harvested on
day 0, 1, 2, and 3. Empty vector
supernatants were used as blank
and samples were analyzed in
triplicate in both assays
Mol Biotechnol
123
4. Walsh, G. (2014). Biopharmaceutical benchmarks 2014. Nature
Biotechnology, 32, 992–1000.
5. Abdiche, Y., Malashock, D., Pinkerton, A., & Pons, J. (2008).
Determining kinetics and affinities of protein interactions using a
parallel real-time label-free biosensor, the Octet. Analytical
Biochemistry, 377, 209–217.
6. Concepcion, J., Witte, K., Wartchow, C., Choo, S., Yao, D.,
Persson, H., et al. (2009). Label-free detection of biomolecular
interactions using BioLayer interferometry for kinetic charac-
terization. Combinatorial Chemistry and High Throughput
Screening, 12, 791–800.
7. Muyldermans, S. (2013). Nanobodies: natural single-domain
antibodies. Annual Review of Biochemistry, 82, 775–797.
8. Frenken, L. G., van der Linden, R. H., Hermans, P. W., Bos, J.
W., Ruuls, R. C., de Geus, B., & Verrips, C. T. (2000). Isolation
of antigen specific llama VHH antibody fragments and their high
level secretion by Saccharomyces cerevisiae. Journal of
Biotechnology, 78, 11–21.
9. McCue, J. T., Selvitelli, K., & Walker, J. (2009). Application of a
novel affinity adsorbent for the capture and purification of
recombinant factor VIII compounds. Journal of Chromatography
A, 1216, 7824–7830.
10. Kotin, R. M. (2011). Large-scale recombinant adeno-associated
virus production. Human Molecular Genetics, 20, R2–R6.
11. Hermans, P., Adams, H., & Detmers, F. (2014). Purification of
antibodies and antibody fragments using CaptureSelect affinity
resins. Methods in Molecular Biology, 1131, 297–314.
12. Eifler, N., Medaglia, G., Anderka, O., Laurin, L., & Hermans, P.
(2014). Development of a novel affinity chromatography resin for
platform purification of lambda fabs. Biotechnology Progress, 30,
1311–1318.
13. Hermans, P., Grit, G., & Blokland, S. (2013). CaptureSelect
affinity ligands for antibody detection and characterization. http://
www.fortebio.com/documents/ForteBio_App_Note_9.pdf.
14. Eustace, D. (2011). Quantitation of recombinant human factor IX
(rFIX) in bioreactor harvest samples using bio-layer interfer-
ometry. http://www.fortebio.com/doc_download.html?docid=188.
15. Boersma, Y. L., & Pluckthun, A. (2011). DARPins and other
repeat protein scaffolds: Advances in engineering and applica-
tions. Current Opinion in Biotechnology, 22, 849–857.
Mol Biotechnol
123
